Please use this identifier to cite or link to this item:
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL|
Antioxidanst in differentiation of leukemic cells
|Authors:||López-Lluch, Guillermo ; Siendones, Emilio ; Moreno Fernández-Ayala, Daniel José; Navas, Plácido|
|Publisher:||Nova Science Publishers|
|Citation:||New cell differentiation research topics: 79-116 (2007)|
|Abstract:||The therapy of leukaemia based on the use of compounds able to reinitiate the differentiation program has been extensively studied. The use of calcitriol (1,25D3) or trans-retinoic acid (ATRA) in myeloid or monocytic leukemic cell differentiation has been also clinically taken into consideration. Both are natural compounds accepted at relatively high doses by the organism, however, several other secondary effects take place because their other respective main functions different than regulating the differentiation program in cancerous cells. To avoid the secondary effects due to overloading of both, ATRA or 1,25D3, therapies based on the co-administration of other natural compounds such as vitamin C, vitamin E, polyphenols, caretonoids or other antioxidants acting as anti-cancer active compounds have been taking into consideration. In several cases, these natural compounds do not affect by themselves the differentiation program in leukemic cells but they are able to enhance the effect of the differentiation-active compounds such as ATRA or 1,25D3. The present chapter reviews the effect of the combination of these natural antioxidant compounds on the treatment of leukemic cells and will try to define the probable common mechanism of action for this plethora of substances.|
|Description:||38 páginas, 3 figuras, 1 tabla. Editor: Hitoshi Saitama.|
|Appears in Collections:||(CABD) Libros y partes de libros|
Files in This Item:
There are no files associated with this item.
Show full item record
WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.